An economic evaluation of donepezil in the treatment of Alzheimer's disease

Clinical Therapeutics

Volumn 20, Issue 4, 1998, Pages 838-850

  Small, Gary W ^a,b   Donohue, Jane A ^c,d   Brooks, Rochelle L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Consumer Health Sciences ^*  (United States)

^d Research Park ^*  (United States)

Author keywords

Alzheimer's disease; Cost of illness; Donepezil; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; DONEPEZIL; ESTROGEN; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 0031718553     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80145-8     Document Type: Note

References (23)

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997;278:1363-1371.
2. Evans D. Estimated prevalence of Alzheimer's disease in the United States. Milhank Q. 1990;68:267-289.
3. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84: 1261-1264.
4. Max W. The cost of Alzheimer's disease: Will drug treatment ease the burden? PharmacoEconomics. 1996;9:5-10.
5. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff. 1993;12:165-176.
6. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. Arch Neurol. 1997;54:687-693.
7. Huang L, Cartwright WS, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep. 1988;103:3-7.
8. Whitehouse PJ. Pharmacoeconomics of dementia. Alzheimer Dis Assoc Disord. 1997;11(Suppl 5):S22-S33.
9. Small GW. Tacrine for treating Alzheimer's disease. JAMA. 1992;268:2564-2565.
10. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface. 1994;7:130-138.
11. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther. 1997;19: 330-345.
12. Knopman D, Schneider L, Davis K, et al. Long term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology. 1996;47:166-177.
13. Rogers SL, Friedhoff LT, Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7:293-303.
14. Corder LS, Woodbury MA, Manton KG. Proxy response patterns among the aged: Effects on estimates of health status and medical care utilization from the 1982-1984 long-term care surveys. J Clin Epidemiol. 1996;49:173-182.
15. Teri L, Traux P, Logsdon R, et al. Assessment of behavioral problems in dementia: The Revised Memory and Behavior Problems Checklist. Psychol Aging. 1992;7: 622-631.
16. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1997.
17. Kaufer DI, Cummings JL, Christine D. Effects of tacrine on behavioral symptoms in Alzheimer's disease: An open label study. J Geriatr Psychiatry Neurol. 1996; 9:1-6.
18. Cummings JL, Cyrus PA, Bieber F, et al. The effect of metrifonate on the cognitive, functional and behavioral symptoms of Alzheimer's disease patients. Paper presented at the 11th Annual Scientific Meeting of the American Association for Geriatric Psychiatry, San Diego, California, March 8-11, 1998.
19. Colerick EL, George LK. Predictors of institutionalization among caregivers of patients with Alzheimer's disease. J Am Geriatr Soc. 1986;34:493-498.
20. Pruchno RA, Michaels JE, Potashnik SL. Predictors of institutionalization among Alzheimer disease victims with caregiving spouses. J Gerontol. 1990;45:S259-S266. Supplement.
21. Heyman A, Wilkinson WE, Hurwitz BJ, et al. Early-onset Alzheimer's disease: Clinical predictors of institutionalization and death. Neurology. 1987;37:980-984.
22. Knopman DS, Kitto J, Deinard S, et al. Longitudinal study of death and institutionalization in patients with primary degenerative dementia. J Am Geriatr Soc. 1988;36:108-112.
23. O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45-52.